4D Molecular Therapeutics Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
201
- Stock Symbol
-
FDMT
- Investments
-
1
- Share Price
-
$3.75
- (As of Thursday Closing)
4D Molecular Therapeutics General Information
Description
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
Contact Information
Website
www.4dmoleculartherapeutics.comCorporate Office
- 5858 Horton Street
- Suite 455
- Emeryville, CA 94608
- United States
Corporate Office
- 5858 Horton Street
- Suite 455
- Emeryville, CA 94608
- United States
4D Molecular Therapeutics Stock Performance
As of 20-Mar-2025, 4D Molecular Therapeutics’s stock price is $3.75. Its current market cap is $174M with 46.3M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.75 | $3.79 | $3.66 - $36.25 | $174M | 46.3M | 885K | -$2.98 |
4D Molecular Therapeutics Financials Summary
As of 31-Dec-2024, 4D Molecular Therapeutics has a trailing 12-month revenue of $37K.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | (219,570) | (219,570) | 561,681 | 508,272 |
| Revenue | 37 | 37 | 20,723 | 3,129 |
| EBITDA | 4,612,082 | 4,612,082 | 4,286,952 | (106,187) |
| Net Income | (160,868) | (160,868) | (100,837) | (107,494) |
| Total Assets | 560,384 | 560,384 | 339,891 | 261,846 |
| Total Debt | 24,606 | 24,606 | 14,671 | 16,124 |
4D Molecular Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
4D Molecular Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
4D Molecular Therapeutics Comparisons
Industry
Financing
Details
4D Molecular Therapeutics Competitors (40)
One of 4D Molecular Therapeutics’s 40 competitors is Bluebird Bio, a Formerly VC-backed company based in Somerville, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Bluebird Bio | Formerly VC-backed | Somerville, MA | ||||
| Caribou Biosciences | Formerly VC-backed | Berkeley, CA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Gilead Sciences | Formerly VC-backed | Foster City, CA | ||||
| Renova Therapeutics | Venture Capital-Backed | Carlsbad, CA |
4D Molecular Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
4D Molecular Therapeutics Patents
4D Molecular Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023230885-A1 | Adeno-associated virus variant capsids with improved lung tropism and uses thereof | Pending | 07-Mar-2022 | ||
| EP-4490301-A2 | Adeno-associated virus variant capsids with improved lung tropism and uses thereof | Pending | 07-Mar-2022 | ||
| CA-3215812-A1 | Compositions and methods for treatment of ocular disease associated with angiogenesis | Pending | 27-Apr-2021 | ||
| AU-2022266774-A9 | Compositions and methods for treatment of ocular disease associated with angiogenesis | Active | 27-Apr-2021 | ||
| AU-2022266774-A1 | Compositions and methods for treatment of ocular disease associated with angiogenesis | Active | 27-Apr-2021 | C12N15/86 |
4D Molecular Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
4D Molecular Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
4D Molecular Therapeutics Investments (1)
4D Molecular Therapeutics’s most recent deal was a Corporate Asset Purchase with Aevitas Therapeutics (Short-Form Human Complement Factor H). The deal was made on 24-Apr-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Aevitas Therapeutics (Short-Form Human Complement Factor H) | 24-Apr-2023 | Corporate Asset Purchase | Buildings and Property |
4D Molecular Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 30, 2024
35.06 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,946
Rank
Percentile
Pharmaceuticals
Industry
of 847
Rank
Percentile
Biotechnology
Subindustry
of 366
Rank
Percentile
4D Molecular Therapeutics FAQs
-
When was 4D Molecular Therapeutics founded?
4D Molecular Therapeutics was founded in 2013.
-
Where is 4D Molecular Therapeutics headquartered?
4D Molecular Therapeutics is headquartered in Emeryville, CA.
-
What is the size of 4D Molecular Therapeutics?
4D Molecular Therapeutics has 201 total employees.
-
What industry is 4D Molecular Therapeutics in?
4D Molecular Therapeutics’s primary industry is Drug Discovery.
-
Is 4D Molecular Therapeutics a private or public company?
4D Molecular Therapeutics is a Public company.
-
What is 4D Molecular Therapeutics’s stock symbol?
The ticker symbol for 4D Molecular Therapeutics is FDMT.
-
What is the current stock price of 4D Molecular Therapeutics?
As of 20-Mar-2025 the stock price of 4D Molecular Therapeutics is $3.75.
-
What is the current market cap of 4D Molecular Therapeutics?
The current market capitalization of 4D Molecular Therapeutics is $174M.
-
What is 4D Molecular Therapeutics’s current revenue?
The trailing twelve month revenue for 4D Molecular Therapeutics is $37K.
-
Who are 4D Molecular Therapeutics’s competitors?
Bluebird Bio, Caribou Biosciences, Adaptimmune Therapeutics, Gilead Sciences, and Renova Therapeutics are some of the 40 competitors of 4D Molecular Therapeutics.
-
What is 4D Molecular Therapeutics’s annual earnings per share (EPS)?
4D Molecular Therapeutics’s EPS for 12 months was -$2.98.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
